Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2014—HTG Molecular Diagnostics and OvaGene Oncology entered a manufacturing supply agreement in which OvaGene will design and develop its proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.
June 2014—Arlington Scientific received FDA Center for Biologics Evaluation and Research clearance for the ASiManager-AT in rapid plasma reagin (RPR) interpretation and screening of blood donors.
June 2014—Siemens Healthcare submitted a Premarket Approval application for its Advia Centaur HIV Ag/Ab Combo assay to the Food and Drug Administration.
June 2014—Siemens Healthcare launched the Hematek 3000 System, a semiautomated slide staining system that can stain up to 60 slides per hour.
June 2014—Leica Biosystems joined the GHX electronic trading exchange for U.S. customers. The GHX Exchange enables provider organizations to send their electronic data interchange (EDI) transactions through a single connection as opposed to multiple point-to-point EDI connections, thus allowing Leica’s customers to view their transactions and address discrepancies in real time.
June 2014—InSphero, working with researchers at the Medical University Innsbruck in Tyrol, Austria, published a study highlighting development of a novel 3D cell culture model for non-small cell lung cancer.
June 2014—PlatinumCode added pediatric pressure-activated safety heel stick devices to its lineup. The devices come in four sizes and colors, with a range of blade depths.
June 2014—Designed for applications that use common, disposable conical tubes, JA-14.50 rotors from Beckman Coulter extend the applications and flexibility of the company’s Avanti centrifuges.
June 2014—Eppendorf announced the epMotion automation method for Illumina’s TruSeq Stranded Total RNA library preparation kit for next-generation sequencing as “Illumina Qualified.”
June 2014—Quest Diagnostics launched MyQuest by Care360 at QuestDiagnostics.com/MyQuest, a secure patient portal that enables patients to view copies of their lab test reports from Quest.
